Derma AD
Derma AD
Derma AD
DERMATITIS
Goals and Objectives
▪ The purpose of this module is to help develop a clinical
approach to the evaluation and initial management of patients
with atopic dermatitis.
2
Atopic Dermatitis (AD)
• chronic, highly pruritic (itchy) inflammatory
skin disease.
• one of the most common skin disorders in
children
• The disorder results in significant morbidity
and adversely affects quality of life.
• The intense itching characteristic of the
disease often leads to skin trauma and
significant sleep disturbances
AD is a primary skin barrier defect
that facilitates the development of
other atopic condition
•Severe AD in infancy is a major risk factor for allergies to egg and peanut.
• Dry skin
ACUTE:
poorly defined erythematous patches, papules with or
without scale, skin is “puffy” & edematous, erosions, crusted,
excoriations (from scratching),secondarily infected (S.
aureus), pustules.
CHRONIC :
•LICHENIFICATION
•FISSURES
•PERIORBITAL HYPERPIGMENTATION
• Other features:
• Allergy or elevated IgE
• Severe Combined Immunodeficiency Syndrome –
• Infants presenting in the first year of life with failure to thrive,
diarrhea, a generalized scaling erythematous rash, and recurrent
cutaneous and/or systemic infections
• Wiskott–Aldrich syndrome
• Cutaneous findings almost indistinguishable from AD
• thrombocytopenia,
• variable abnormalities in humoral and cellular immunity, and
• recurrent severe bacterial infections
• It is important to recognize that an adult who presents
with an eczematous dermatitis with :
• no history of childhood eczema, respiratory allergy, or
atopic family history may have allergic contact
dermatitis
MANAGEMENT
4 MAJOR
COMPONENTS Anti Inflammatory
Antibacterial
Antipruritic
Moisturizer
Topical Steroids
-are the first-line pharmacologic treatments for AD.
-used to treat acute inflammation.
-effectively control atopic flares through their anti-inflammatory, antiproliferative, and
immunosuppressive actions.
-applied to the red, itchy or inflamed areas on the skin.
-Ointments are preferred vehicles over creams.
-least potent preparation required to control AD (particularly in sensitive areas such as the face, neck,
groin and underarms) should be utilized.
-local side effects of long-term topical corticosteroid use : striae (stretch marks), petechiae (small
red/purple spots), telangiectasia (small, dilated blood vessels on the surface of the skin), skin thinning,
atrophy and acne.
Topical Steroid Strength
Potency Class Example Agent
• Remember to look at the class not the Super I Clobetasol 0.05%
high
percentage
High II Fluocinonide 0.05%
• Clobetasol 0.05% is stronger than Medium III – V Triamcinolone ointment 0.1%
hydrocortisone 1% Triamcinolone cream 0.1%
Triamcinolone lotion 0.1%
• When several are listed, they are listed in
Low VI – Fluocinolone 0.01%
order of strength VII Desonide 0.05%
Hydrocortisone 1%
• Triamcinolone ointment is stronger Hydrocortisone 2.5%
than triamcinolone cream or lotion
because of the nature of the vehicle
Topical Calcineurin Inhibitors
-TCIs are immunosuppressant agents that have also been shown
to be safe and effective for the treatment of AD, as well as the
prophylaxis of AD flares.
-second line agents
-TCIs—pimecrolimus and tacrolimus
-reserved for patients with persistent disease and/or frequent fares
that would require continuous topical corticosteroid treatment, or in
patients severely affected in sensitive skin areas.
-local adverse effects of TCIs: skin burning and irritation
Moisturizer
• May be the primary treatment for mild disease and must be part of the
regimen for moderate and severe disease.